928 results match your criteria Acneiform Eruptions


Brief Report: Pembrolizumab in Combination With Erlotinib or Gefitinib as First-Line Therapy for Advanced Non-Small-Cell Lung Cancer With Sensitizing EGFR Mutation.

J Thorac Oncol 2018 Dec 4. Epub 2018 Dec 4.

South Texas Accelerated Research Therapeutics, 4383 Medical Dr, San Antonio, TX 78229, USA.

Introduction: Anti-EGFR agents are standard treatments for patients with EGFR-mutant advanced NSCLC. The feasibility of combining erlotinib or gefitinib with anti-PD1 immunotherapy pembrolizumab was evaluated in the phase 1/2 KEYNOTE-021 (NCT02039674) study.

Methods: Adults with previously untreated stage IIIB/IV EGFR-mutant NSCLC were treated with pembrolizumab 2 mg/kg IV every 3 weeks plus oral erlotinib 150 mg daily in cohort E or oral gefitinib 250 mg daily in cohort F, using a 3+3 design with cohort expansion. Read More

View Article
December 2018

Clinical Experience of Chinese Herbal Medicine Ameliorates Dermatologic Events from Epidermal Growth Factor Receptor Inhibitors for Lung Cancer: A Case Series.

Explore (NY) 2018 Nov 6. Epub 2018 Nov 6.

Department of Chinese Medicine, Kaohsiung Chang Gung Memorial Hospital and Chang Gung University College of Medicine, Kaohsiung 83301, Taiwan; Graduate Institute of Integrated Medicine, College of Chinese Medicine, Research Center for Chinese Medicine & Acupuncture, China Medical University, Taichung 40402, Taiwan. Electronic address:

Background: To summarize the clinical efficacy and safety of Chinese herbal medicine (CHM) in the treatment of dermatologic events resulting from epidermal growth factor receptor (EGFR) inhibitors according to our experience of ten patients.

Methods: Four males and six females, 35-73 years old, mainly with acneiform rash associated with EGFR inhibitors on the face, scalp, perineum, four limbs, and upper trunk, were treated at our traditional Chinese medicine (TCM) clinic in 2016 and 2017. CHM was prescribed thrice daily for 3. Read More

View Article
November 2018
2 Reads

Instrumental evaluation sensitively detects subclinical skin changes by the epidermal growth factor receptor inhibitors and risk factors for severe acneiform eruption.

J Dermatol 2018 Nov 7. Epub 2018 Nov 7.

Department of Dermatology, Mie University Graduate School of Medicine, Tsu, Japan.

Epidermal growth factor receptor inhibitors (EGFRI), EGFR tyrosine kinase inhibitors (TKI) and anti-EGFR antibodies commonly develop skin toxicities including acneiform eruption (AfE). However, precise skin changes and risk factors for severe AfE are still unclear. The objective of the current study was elucidation of the useful parameters for early and sensitive detection of the skin changes by EGFRI. Read More

View Article
November 2018
7 Reads

Retinoic acid co-treatment aggravates severity of dioxin-induced skin lesions in hairless mice via induction of inflammatory response.

Biochem Biophys Res Commun 2018 Dec 31;506(4):854-861. Epub 2018 Oct 31.

NRC Kurchatov Institute, Moscow, Russian Federation. Electronic address:

Exposure to toxic halogenated polyaromatic hydrocarbons, of which 2,3,7,8-tetrachlorodibenzo-p-dioxin (TCDD) is the most potent, induces diverse skin pathologies in humans, including chloracne, hyperkeratosis, hamartomas, etc. While the toxic effects of TCDD have been extensively studied, effective approaches to their treatment are still lacking. Retinoids are commonly used in therapy of acneiform skin diseases. Read More

View Article
December 2018
3 Reads

Toxic Side Effects of Targeted Therapies and Immunotherapies Affecting the Skin, Oral Mucosa, Hair, and Nails.

Am J Clin Dermatol 2018 Nov;19(Suppl 1):31-39

Institut Universitaire du Cancer Toulouse - Oncopole, 1 avenue Irène Joliot-Curie, 31059, TOULOUSE Cedex 9, France.

Targeted therapies and immunotherapies are associated with a wide range of dermatologic adverse events (dAEs) resulting from common signaling pathways involved in malignant behavior and normal homeostatic functions of the epidermis and dermis. Dermatologic toxicities include damage to the skin, oral mucosa, hair, and nails. Acneiform rash is the most common dAE, observed in 25-85% of patients treated by epidermal growth factor receptor and mitogen-activated protein kinase kinase inhibitors. Read More

View Article
November 2018
12 Reads

Adverse cutaneous effects of neratinib.

J Dermatolog Treat 2018 Nov 28:1-2. Epub 2018 Nov 28.

a Department of Dermatology , Wake Forest School of Medicine , Winston-Salem , NC , USA.

Neratinib is a tyrosine kinase inhibitor that was FDA-approved for extended adjuvant treatment in adults with human epidermal growth factor receptors-2 (HER-2) positive breast cancer in 2017. Due to the novelty of the drug, there are no current reports in the literature of adverse cutaneous effects associated with neratinib therapy. We present a case of a woman on neratinib for HER-2 positive infiltrating ductal carcinoma of the right breast who presented to the dermatology clinic with changes to the fingernails, acne, and a rash on the face. Read More

View Article
November 2018

A phase 1b study of afatinib in combination with standard-dose cetuximab in patients with advanced solid tumours.

Eur J Cancer 2018 Nov 1;104:1-8. Epub 2018 Oct 1.

Medical Oncology Division, START Madrid Centro Integral Oncológico Clara Campal, Calle de Oña, 10, 28050, Madrid, Spain. Electronic address:

This phase 1b, open-label trial assessed the combination of afatinib, an ErbB family blocker, with cetuximab, an epidermal growth factor receptor (EGFR) monoclonal antibody, in heavily pretreated patients with unselected/EGFR wild-type, advanced solid tumours. In Part A, the maximum tolerated dose (MTD) of afatinib + cetuximab was evaluated using a 3 + 3 dose-escalation design; the starting dose was afatinib 30 mg/day plus cetuximab 250 mg/m/week (after cetuximab 400 mg/m loading dose), escalating to afatinib 40 mg/day. Part B further evaluated safety and tolerability at the MTD and preliminary anti-tumour activity in three patient cohorts with squamous non-small cell lung cancer (NSCLC), head and neck squamous cell carcinoma (HNSCC) and other solid tumours. Read More

View Article
November 2018
4 Reads

Acneiform eruptions: An unusual dermatological side effect of ribavirin.

Dermatol Ther 2018 09 19;31(5):e12679. Epub 2018 Sep 19.

Department of Dermatology and Venereology, All India Institute of Medical Sciences, New Delhi, India.

View Article
September 2018
1 Read

Skin Disorders and Primary Tumor Location as Prognostic Factors in Patients with Metastatic Colorectal Cancer Treated with Cetuximab and Chemotherapy

Asian Pac J Cancer Prev 2018 Aug 24;19(8):2325-2330. Epub 2018 Aug 24.

Department of Pharmacy, National Hospital Organization Hokkaido Cancer Center, Japan. Email:

Background: Cetuximab-induced skin disorder is common in colorectal cancer (CRC), and is known to affect prolonged overall survival (OS). Patients with left-sided CRC survive longer than those with right-sided CRC, among those treated with combination cetuximab and chemotherapy. However, no study has evaluated patient prognosis in terms of OS and progression-free survival (PFS) in relation to both tumor location and skin disorder. Read More

View Article
August 2018
2 Reads

Induction chemotherapy with carboplatin, nab-paclitaxel and cetuximab for at least N2b nodal status or surgically unresectable squamous cell carcinoma of the head and neck.

Oral Oncol 2018 Sep 19;84:46-51. Epub 2018 Jul 19.

West Cancer Center at the University of Tennessee, United States. Electronic address:

Background: Although induction studies of TPF in SCCHN have not improved outcomes compared to chemoradiotherapy alone, phase II studies of weekly carboplatin (CbP), paclitaxel and cetuximab (C225) have shown promising results. Nano-albumin-paclitaxel (nab-paclitaxel) based chemotherapy has demonstrated a higher response rate (RR) than solvent-based paclitaxel in squamous cell carcinoma of the lung with favorable toxicity.

Materials And Methods: Patients with treatment naïve SCCHN of any site with ≥N2b disease or that was unresectable by strict criteria were eligible. Read More

View Article
September 2018
1 Read

Hypopigmented and acneiform lesions: An unusual initial presentation of adult-onset multisystem Langerhans cell histiocytosis.

Indian J Dermatol Venereol Leprol 2018 Sep-Oct;84(5):621-626

Department of Internal Medicine and Hematology, Postgraduate Institute of Medical Education and Research, Chandigarh, India.

View Article
August 2018
1 Read
1.325 Impact Factor

Phase I dose-escalation trial of Sym004, an anti-EGFR antibody mixture, in Japanese patients with advanced solid tumors.

Cancer Sci 2018 Oct 25;109(10):3253-3262. Epub 2018 Sep 25.

National Cancer Center Hospital East, Kashiwa, Chiba, Japan.

Sym004 is a 1:1 mixture of two antibodies targeting non-overlapping epitopes of the epidermal growth factor receptor that antagonizes ligand binding and induces receptor downregulation. In preclinical models, it has superior antitumor activity to cetuximab and panitumumab. Japanese adults aged ≥20 years with an Eastern Cooperative Oncology Group status of 0/1 and life expectancy ≥3 months were eligible. Read More

View Article
October 2018
6 Reads

A phase I study to assess afatinib in combination with carboplatin or with carboplatin plus paclitaxel in patients with advanced solid tumors.

Cancer Chemother Pharmacol 2018 Nov 7;82(5):757-766. Epub 2018 Aug 7.

King's College London, Guy's Hospital, 3rd Floor Bermondsey Wing, London, UK.

Purpose: Afatinib, an irreversible ErbB family blocker, has demonstrated preclinical antitumor activity with chemotherapy.

Methods: As part of a phase I trial in patients with advanced solid tumors (NCT00809133; 3 + 3 dose-escalation design), we determined the maximum tolerated dose (MTD) of afatinib with carboplatin (A/C) or with carboplatin plus paclitaxel (A/C/P). Starting doses: afatinib 20 mg/day, carboplatin AUC6 (A/C) with paclitaxel 175 mg/m (A/C/P) (chemotherapy: Day 1 of 21-day cycles). Read More

View Article
November 2018

Retrospective Chart Review of Cutaneous Adverse Events Associated with Tremelimumab in 17 Patients.

Am J Clin Dermatol 2018 Dec;19(6):899-905

University of Texas McGovern Medical School, Houston, TX, USA.

Background And Objectives: Tremelimumab is a monoclonal human antibody that inhibits cytotoxic T-lymphocyte-associated antigen 4, giving rise to increased T cell activation and interleukin-2 release. While this activation of the immune system provides a mechanism to recognize and destroy cancer cells, it also leads to off-target immune-related adverse events. Ipilimumab is a US Food and Drug Administration-approved anti-cytotoxic T-lymphocyte-associated antigen 4 antibody, which has a high incidence of cutaneous adverse events. Read More

View Article
December 2018
10 Reads

EGFR inhibitor-induced cut-like skin lesions of the fingers.

BMJ Case Rep 2018 Aug 1;2018. Epub 2018 Aug 1.

Lucy Curci Cancer Center, Eisenhower Health, Rancho Mirage, California, USA.

Cetuximab and osimertinib are epidermal growth factor receptors (EGFRs) inhibitors used in the treatment of several malignancies. These agents have been associated with several skin lesions, the most common being papulopustular acneiform rash involving the face, neck, chest and back. Herein, we describe a unique toxic effect of these agents involving the fingertips and lateral aspects of fingers in a small patient series. Read More

View Article
August 2018
12 Reads

Galli-Galli Disease Presenting as a Lentigo-like Eruption: A Further Clinical Feature in the Wide Spectrum of Reticulate Pigment Disorders.

Acta Dermatovenerol Croat 2017 Dec;25(4):300-302

Dario Didona, MD, Prima Divisione Dermatologia Istituto Dermopatico dell'Immacolata, Via dei Monti di Creta 104, 00167 Rome , Italy;

Dear Editor, Reticulate pigmentary disorders (RPD) is a term used to classify a spectrum of several acquired and congenital disorders. Different clinical features can be present, including a reticular pattern and a freckle-like pattern with hyper- or hypo-pigmented macules (1). Dowling-Degos disease (DDD), an autosomal dominant genodermatosis, is the main type of RPD (2). Read More

View Article
December 2017
5 Reads

First-line mFOLFOX plus cetuximab followed by mFOLFOX plus cetuximab or single-agent cetuximab as maintenance therapy in patients with metastatic colorectal cancer: Phase II randomised MACRO2 TTD study.

Eur J Cancer 2018 Sep 24;101:263-272. Epub 2018 Jul 24.

Hospital Universitario Clínico San Carlos, Instituto de Investigación Hospital Clínico San Carlos (IdISSC), University Complutense, CIBERONC, Madrid, Spain.

Background: This multicentre, randomised, and phase II study evaluated mFOLFOX+cetuximab followed by maintenance mFOLFOX+cetuximab or single-agent cetuximab in metastatic colorectal cancer (mCRC) patients (NCT01161316).

Patients And Methods: Previously, untreated mCRC patients (wild-type KRAS) were randomised to receive cetuximab+mFOLFOX-6 (8 cycles for 2 weeks) followed by maintenance therapy: single-agent cetuximab (Arm-A) or mFOLFOX-6 + cetuximab (Arm-B) until progression. Primary endpoint was progression-free survival (PFS) at 9 months. Read More

View Article
September 2018
1 Read

Pattern of skin diseases amongst children attending a dermatology clinic in Lagos, Nigeria.

Pan Afr Med J 2018 19;29:162. Epub 2018 Mar 19.

Department of Medicine, College of Medicine University of Lagos, Idi-araba, Lagos, Nigeria.

Introduction: Skin diseases constitute a major health problem affecting a large proportion of the population including children causing distress and disability. This study aimed to document the spectrum and frequency of skin diseases of children who attended the dermatology outpatient clinic of the Lagos University Teaching Hospital (LUTH) Lagos, Nigeria.

Methods: A cross-sectional study of children (18 years old and below) who attended the dermatology clinic between January 2004 and December 2016. Read More

View Article
August 2018
12 Reads

A case report of toxic epidermal necrolysis associated with AZD-9291.

Drug Des Devel Ther 2018 11;12:2163-2167. Epub 2018 Jul 11.

Department of Dermatology, The First Affiliated Hospital of Nanjing Medical University, Nanjing, Jiangsu, The People's Republic of China,

Epidermal growth factor receptor-tyrosine kinase inhibitors (EGFR-TKIs) are a strain of small molecule inhibitors mainly used to treat the metastatic non-small cell lung cancer. Their predominant adverse effect is skin toxicity, usually manifested as acneiform rash, skin fissure, xerosis, and paronychia. Severe epidermal necrosis and exfoliation rarely occur. Read More

View Article
December 2018
15 Reads

Tofacitinib (Selective Janus Kinase Inhibitor 1 and 3): A Promising Therapy for the Treatment of Alopecia Areata: A Case Report of Six Patients.

Int J Trichology 2018 May-Jun;10(3):103-107

Department of Dermatology, Cutis Academy of Cutaneous Sciences, Bengaluru, Karnataka, India.

Background: Alopecia areata (AA) is a chronic autoimmune disorder characterized by patchy loss of hair from scalp, beard, eyebrows, or rarely even body hair. Rarely, the disease can be widespread and severe leading to loss of entire scalp and body hair causing apprehension and psychological stress in patients. Management of such cases is equally difficult with the available options of topical and systemic immunosuppressant. Read More

View Article
July 2018
9 Reads

Oral Isotretinoin for the treatment of Aripiprazol-induced acneiform rash.

Dermatol Ther 2018 Jul 17;31(4):e12637. Epub 2018 Jul 17.

Departament of Dermatology, Hospital Santa Ana, Motril, Spain.

Acneiform rash is a commonly reported side effect to certain types of medications, including antipsychotic agents. Its clinical presentation consists mainly of papulopustular lesions. Other types of lesions, such as nodular or cystic, can also be observed. Read More

View Article
July 2018
10 Reads

An update on Chinese herbal medicines as adjuvant treatment of anticancer therapeutics.

Biosci Trends 2018 ;12(3):220-239

Department of Traditional Chinese Medicine, Shandong Provincial Hospital affiliated to Shandong University.

Numerous studies have indicated that in cancer treatment Chinese herbal medicines in combination with chemo-, radio-, or targeted-therapy can be used to enhance the efficacy of and diminish the side effects and complications caused by these therapies. Therefore, an understanding of Chinese herbal medicines is needed by physicians and other health care providers. This review provides an update on Chinese herbal medicines as adjuvant treatment of anticancer therapeutics. Read More

View Article
October 2018
10 Reads

An acneiform eruption secondary to iododerma.

JAAD Case Rep 2018 Jun 30;4(5):468-470. Epub 2018 Apr 30.

Department of Dermatology, University of Michigan, Ann Arbor, Michigan.

View Article
June 2018
1 Read

Phase II Studies with Refametinib or Refametinib plus Sorafenib in Patients with -Mutated Hepatocellular Carcinoma.

Clin Cancer Res 2018 Oct 27;24(19):4650-4661. Epub 2018 Jun 27.

Division of Liver Diseases, Icahn School of Medicine at Mount Sinai, New York, New York.

Refametinib, an oral MEK inhibitor, has demonstrated antitumor activity in combination with sorafenib in patients with -mutated hepatocellular carcinoma (HCC). Two phase II studies evaluated the efficacy of refametinib monotherapy and refametinib plus sorafenib in patients with -mutant unresectable or metastatic HCC. Eligible patients with mutations of cell-free circulating tumor DNA (ctDNA) determined by beads, emulsion, amplification, and magnetics technology received twice-daily refametinib 50 mg ± sorafenib 400 mg. Read More

View Article
October 2018
13 Reads

Effect of Adding Motolimod to Standard Combination Chemotherapy and Cetuximab Treatment of Patients With Squamous Cell Carcinoma of the Head and Neck: The Active8 Randomized Clinical Trial.

JAMA Oncol 2018 Nov;4(11):1583-1588

Moores Cancer Center, University of California San Diego, La Jolla.

Importance: Immunotherapy for recurrent and/or metastatic (R/M) squamous cell carcinoma of the head and neck (SCCHN) is promising. The toll-like receptor 8 (TLR8) agonist motolimod may stimulate innate and adaptive immunity.

Objective: To determine whether motolimod improves outcomes for R/M SCCHN when combined with standard therapy. Read More

View Article
November 2018
6 Reads

A phase I study of LY3164530, a bispecific antibody targeting MET and EGFR, in patients with advanced or metastatic cancer.

Cancer Chemother Pharmacol 2018 Sep 20;82(3):407-418. Epub 2018 Jun 20.

Cancer Medicine Division, MD Anderson Cancer Center, The University of Texas, Houston, TX, USA.

Purpose: The phase I study characterized the safety, pharmacokinetics, anti-tumor activity, and recommended phase II dose/schedule of LY3164530 in patients with advanced or metastatic cancer.

Methods: Patients received LY3164530 on days 1 and 15 (Schedule 1: 300, 600, 1000, and 1250 mg) or Days 1, 8, 15, and 22 (Schedule 2: 500 and 600 mg) of each 28 days cycle. Dose escalation used a modified toxicity probability interval model. Read More

View Article
September 2018
3 Reads

Acneiform follicular mucinosis: an indolent follicular mucinosis variant unrelated to mycosis fungoides?

Clin Exp Dermatol 2018 Dec 30;43(8):921-924. Epub 2018 May 30.

Dermatology Service, Department of Medicine, Memorial Sloan Kettering Cancer Center and Weill Cornell Medicine, New York, NY, USA.

Follicular mucinosis (FM) can present as an acneiform eruption, and is usually a benign variant of primary FM unrelated to cutaneous T-cell lymphoma (CTCL). We report two cases of women in their twenties who presented with an acneiform rash on the face, arms and back. In both cases, pathological evaluation of the facial papules revealed predominantly mucinous degeneration of the follicular epithelium, with insufficient lymphocytic infiltration or atypia to diagnose mycosis fungoides. Read More

View Article
December 2018
1 Read

Molecular Docking for Prediction and Interpretation of Adverse Drug Reactions.

Comb Chem High Throughput Screen 2018 ;21(5):314-322

Center for Computational Health, IBM T.J. Watson Research Center, Yorktown Heights, NY 10598, United States.

Aim And Objective: Adverse drug reactions (ADRs) present a major burden for patients and the healthcare industry. Various computational methods have been developed to predict ADRs for drug molecules. However, many of these methods require experimental or surveillance data and cannot be used when only structural information is available. Read More

View Article
January 2018
11 Reads

Dermatological aspects of tularaemia: a study of 168 cases.

Clin Exp Dermatol 2018 Oct 14;43(7):770-774. Epub 2018 May 14.

Department of Infectious Diseases, Abant Izzet Baysal University, Faculty of Medicine, Bolu, Turkey.

Background: Tularaemia is a zoonotic infectious disease caused by Francisella tularensis, an aerobic, uncapsulated, gram-negative coccobacillus. Several case reports have appeared on the dermatological manifestations of tularaemia, but relatively few longer-term studies are available.

Aim: To identify skin features of tularaemia that aid in its diagnosis. Read More

View Article
October 2018
2 Reads

Management and grading of EGFR inhibitor-induced cutaneous toxicity.

Future Oncol 2018 Oct 4;14(24):2531-2541. Epub 2018 May 4.

Department of Medical/Clinical Oncology, Christie Hospital, 550 Wilmslow Road, Manchester, UK.

Cutaneous toxicities associated with EGFR inhibitors (EGFRIs) have a significant impact on patient treatment continuation, quality of life and healthcare resource utilization. This paper reviews the current prophylaxis and management of EGFRI-induced cutaneous toxicities in patients with colorectal cancer, and combines these findings with the authors' clinical expertise to define a novel algorithm for healthcare professionals managing patients receiving EGFRIs. This tool includes a grading system based on the location, severity and psychological impact, and provides a standard prescription pack, advice on prophylaxis/self-management of cutaneous symptoms for patients initiating EGFRIs, and essential guidance on subsequent review and treatment escalation. Read More

View Article
October 2018
9 Reads

Vemurafenib in Chinese patients with BRAF mutation-positive unresectable or metastatic melanoma: an open-label, multicenter phase I study.

BMC Cancer 2018 May 3;18(1):520. Epub 2018 May 3.

Key Laboratory of Carcinogenesis and Translational Research (Ministry of Education), Peking University Cancer Hospital & Institute, 52# Fucheng Road, Haidian District, Beijing, 100142, China.

Background: Melanoma is a rare, deadly disease without effective treatment options in China. Vemurafenib is a selective inhibitor of oncogenic BRAF kinase approved in more than 90 countries, based on results obtained primarily in Caucasian patients. Limited data are available regarding the efficacy and safety of vemurafenib in Asian patients. Read More

View Article
May 2018
2 Reads

Esophageal Aperistalsis in a Patient with Lipoid Proteinosis.

Middle East J Dig Dis 2018 Jan 14;10(1):55-58. Epub 2018 Jan 14.

Digestive Disease Research Center, Digestive Disease Research Institute, Tehran University of Medical Sciences, Tehran, Iran.

Lipoid proteinosis is a rare disorder with autosomal recessive inheritance, characterized by progressive deposition of hyaline material in the skin, mucous membrane, and different organs of the body, resulting in a multitude of clinical manifestations. A 34-year-old woman presented with hoarseness, dysphagia, eyelid beeding, and acneiform scars on the facial skin and extremities. The patient was diagnosed clinically as having lipoid proteinosis, which was confirmed by laryngeal biopsy. Read More

View Article
January 2018
15 Reads

Osimertinib: A Novel Dermatologic Adverse Event Profile in Patients with Lung Cancer.

Oncologist 2018 Aug 12;23(8):891-899. Epub 2018 Apr 12.

Memorial Sloan Kettering Cancer Center, New York City, New York, USA

Dermatologic adverse events (dAEs) are common with the use of epidermal growth factor receptor-tyrosine kinase inhibitor (EGFR-TKI) therapy. First- and second-generation agents (erlotinib, gefitinib, and afatinib) are frequently associated with acneiform rash, pruritus, xerosis, and paronychia; the incidence and characterization of these dAEs have been well described. However, there is evidence that the dAE profile is different with third-generation EGFR-TKIs. Read More

View Article
August 2018
1 Read

Targeted Therapy-induced Facial Skin Toxicities: Impact on Quality of Life in Cancer Patients.

Asia Pac J Oncol Nurs 2018 Apr-Jun;5(2):172-177

Keio Cancer Center, Keio University School of Medicine, Tokyo, Japan.

Objective: Targeted therapy-induced facial skin toxicities may reduce overall quality of life (QoL) in cancer patients. We investigated whether facial skin toxicities affect QoL and attempted to identify factors related to QoL in patients with advanced/recurrent cancer.

Methods: We performed a cross-sectional study in 34 outpatients with advanced/recurrent cancer showing targeted therapy-induced facial skin toxicities in Japan between November 2016 and February 2017. Read More

View Article

Folliculotropic Mycosis Fungoides in 20 Korean Cases: Clinical and Histopathologic Features and Response to Ultraviolet A-1 and/or Photodynamic Therapy.

Ann Dermatol 2018 Apr 21;30(2):192-201. Epub 2018 Feb 21.

Department of Dermatology, Kosin University College of Medicine, Busan, Korea.

Background: Folliculotropic mycosis fungoides (FMF) is a variant of mycosis fungoides (MF) that is characterized clinically by variable types of skin eruptions, including plaques, acneiform lesions, and alopecic patches. Histopathologically, FMF is characterized by folliculotropic infiltrates.

Objective: This study was conducted to scrutinize the clinical and histopathologic features of FMF in Koreans and the responses to phototherapy. Read More

View Article
April 2018
9 Reads

Dermatologic Toxicity Occurring During Anti-EGFR Monoclonal Inhibitor Therapy in Patients With Metastatic Colorectal Cancer: A Systematic Review.

Clin Colorectal Cancer 2018 06 13;17(2):85-96. Epub 2017 Dec 13.

Jefferson University Hospitals, Philadelphia, PA.

Monoclonal antibody inhibitors of the epidermal growth factor receptor (EGFR) have been shown to improve outcomes for patients with metastatic colorectal cancer (mCRC) without RAS gene mutations. However, treatment with anti-EGFR agents can be associated with toxicities of the skin, nails, hair, and eyes. Because these dermatologic toxicities can result in treatment discontinuation and affect patient quality of life, their management is an important focus when administering anti-EGFR monoclonal antibodies. Read More

View Article
June 2018
7 Reads

RASopathic comedo-like or cystic lesions induced by Vemurafenib: A model of skin lesions similar but not identical to those induced by dioxins (MADISH).

J Eur Acad Dermatol Venereol 2018 Mar 24. Epub 2018 Mar 24.

Department of Pharmacology and Toxiclogy, University of Geneva.

Background: Patients treated with vemurafenib for metastatic melanoma often develop skin lesions similar to those observed after exposure to dioxin-like compounds. We previously called these lesions MADISH (metabolizing acquired dioxin-induced skin hamartoma) when analysing a case of acute dioxin poisoning.

Objective: We performed a clinical trial aimed at comparing the skin lesions observed under vemurafenib treatment with MADISH in order to bring to light a possible cross-talk between vemurafenib and dioxin pathways. Read More

View Article
March 2018
1 Read

Taking it in the chin: vitamin K1 for the prevention of acneiform rash.

Authors:
M E Lacouture

Ann Oncol 2018 Apr;29(4):796-798

Dermatology Service, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, USA.

View Article

Case sharing of a patient re-challenged with afatinib for EGFR-mutated advanced non-small cell lung cancer.

Authors:
Victor H F Lee

Asia Pac J Clin Oncol 2018 Mar;14 Suppl 1:4-6

Department of Clinical Oncology, Li Ka Shing Faculty of Medicine, The University of Hong Kong, Hong Kong, China.

A 65-year-old female with diabetes mellitus but otherwise good health in the past suffered from cough with occasional blood-stained sputum during initial presentation. The patient was diagnosed with pulmonary poorly differentiated adenocarcinoma with an epidermal growth factor receptor (EGFR) exon 19 deletion and hence received afatinib therapy for 25 months without obvious adverse events except for a grade 1-2 acneiform rash. The disease was stabilized after subsequent cycles of chemotherapy with pemetrexed and carboplatin followed by maintenance pemetrexed. Read More

View Article
March 2018
8 Reads

Crystalline folliculitis revealed by non-aqueous staining technique.

Dermatol Online J 2017 Jul 15;23(7). Epub 2017 Jul 15.

University of Kansas School of Medicine, Kansas City, Kansas.

Necrotizing infundibular crystalline folliculitis (NICF) is a rare superficial folliculitis characterized by expansive deposits of birefringent crystallized lipid. We report a case of NICF in a transplant patient presenting with folliculocentric acneiform papules across the lateral face and neck. Biopsy demonstrated intrafollicular crystalline deposits within an intact epidermis. Read More

View Article
July 2017
10 Reads

Overview of current systemic management of EGFR-mutant NSCLC.

Ann Oncol 2018 Jan;29(suppl_1):i3-i9

Department of Clinical Oncology, The Chinese University of Hong Kong, Hong Kong.

Front-line epidermal growth factor receptor tyrosine kinase inhibitor (EGFR TKI) therapy is the standard of care for lung cancer patients with sensitising EGFR mutations (exon 19 deletion or L858R mutation). Several phase III studies have demonstrated the superiority of gefitinib, erlotinib (first generation of TKIs) or afatinib (second generation) to chemotherapy in progression-free survival and response rates. Drug-related toxicities, such as diarrhoea, acneiform skin rash, mucositis, and paronychia, are frequently encountered in patients who receive EGFR TKIs. Read More

View Article
January 2018
2 Reads

Functional improvements in patients with lymphangioleiomyomatosis after sirolimus: an observational study.

Orphanet J Rare Dis 2018 Feb 20;13(1):34. Epub 2018 Feb 20.

Department of Respiratory Medicine, Peking Union Medical College Hospital, Beijing, China.

Background: Sirolimus has been shown to be effective in patients with lymphangioleiomyomatosis (LAM). We wish to summarize our experience using sirolimus and its effectiveness in LAM patients.

Methods: We analyzed data from 98 patients who were diagnosed with definite or probable sporadic LAM based on the European Respiratory Society diagnosis criteria for LAM in 2010 at Peking Union Medical College Hospital and who had received sirolimus during January 2007 to June 2015. Read More

View Article
February 2018
8 Reads

Acneiform Rash Caused by an Unlikely Drug: Topiramate.

Skin Appendage Disord 2018 Jan 6;4(1):25-28. Epub 2017 Jul 6.

Sección de Micología y, Hospital General "Dr. Manuel Gea González," Mexico City, Mexico.

Topiramate is an antiepileptic drug that can also be used for migraine prophylaxis, weight control, and even for methamphetamine dependence; the dosage margin is wide, and the list of side effects is shorter than with other anticonvulsants. We present the case of a 35-year-old man with a disseminated rash of the trunk and extremities after treatment with 25 mg of topiramate daily as a prophylactic migraine treatment. This case report is useful, as this patient was not polymedicated and had a score of 7 on the Naranjo Adverse Drug Reaction Probability Scale. Read More

View Article
January 2018

Deflazacort-induced Acneiform Eruptions.

J Pharm Bioallied Sci 2017 Oct-Dec;9(4):284-286

Department of Skin & VD, Consultant Dermatologist, Nagpur, India.

A 38-year-old male suffering from a low backache since 3 months was diagnosed as a case of L4-L5 disc prolapse after magnetic resonance imaging examination. He was treated with tolperisone, aceclofenac, and paracetamol in these drugs deflazacort added later. From the 2 day of an addition of deflazacort in the therapy, sharply marginated, infiltrative, and erythematous skin eruptions with discrete itching sensations were seen. Read More

View Article
February 2018
6 Reads

Safety of Combined Treatment With Monoclonal Antibodies and Viscum album L Preparations.

Integr Cancer Ther 2018 03 1;17(1):41-51. Epub 2016 Dec 1.

1 Research Institute Havelhoehe, Berlin, Germany.

Combination strategies involving chemotherapy and monoclonal antibodies (mAb) are commonly used in attempts to produce better clinical outcomes. This practice has led to new and ongoing toxicities that may lead to reductions in dose or noncompliance, limiting the effectiveness of treatment. Viscum album L (VA) preparations are widely used in Europe as additive therapy and have been associated with reduced chemotherapy-related adverse reactions and increased health-related quality of life. Read More

View Article

Pediatric periorificial dermatitis.

Cutis 2017 Dec;100(6):385-388

Department of Dermatology, Mt Sinai West of the Icahn School of Medicine, New York, New York, USA.

Periorificial dermatitis (POD) has been documented in the pediatric population in patients as young as 3 months, with a slight predominance in girls compared to boys. Many patients have a personal or family history of atopic disorders. Periorificial dermatitis typically presents with erythematous to flesh-colored papules and rarely pustules near the eyes, nose, and mouth. Read More

View Article
December 2017
6 Reads

Behçet's disease in the United States: A single center descriptive and comparative study.

Eur J Rheumatol 2017 Dec 3;4(4):239-244. Epub 2017 Nov 3.

Division of Rheumatology, Department of Internal Medicine, University of Michigan, Ann Arbor, Michigan, USA.

Objective: Behçet's disease is heterogeneous with clinical variability across ethnicities and geographic locations. The goal of this study was to analyze the clinical characteristics of our multi-ethnic Behçet's disease cohort at the University of Michigan.

Material And Methods: A detailed patient characterization was performed. Read More

View Article
December 2017
2 Reads

Folliculotropic mycosis fungoides: challenging clinical, histopathological and immunohistochemical diagnosis.

An Bras Dermatol 2017 ;92(5 Suppl 1):73-75

Department of Morphology, Universidade Federal de Juiz de Fora (UFJF) - Juiz de Fora (MG), Brazil.

Mycosis fungoides is a cutaneous T-cell lymphoma with various clinical and pathological presentations. Early lesions are nonspecific, which hinders early diagnosis. The folliculotropic subtype is manifested as acneiform lesions, follicular papules or erythematous plaques mainly on the face, neck and upper trunk. Read More

View Article
March 2018
25 Reads

Phase II Study of Panitumumab in RAS Wild-Type Metastatic Adenocarcinoma of Small Bowel or Ampulla of Vater.

Oncologist 2018 Mar 19;23(3):277-e26. Epub 2017 Dec 19.

Department of Gastrointestinal Medical Oncology, Division of Cancer Medicine, Houston, Texas, USA

Lessons Learned: Panitumumab has no clinical activity in metastatic RAS wild-type small bowel adenocarcinoma (SBA) and ampullary adenocarcinoma (AAC), possibly due to the foregut and midgut derivation of small bowel and ampulla.These results, along with findings from genomic characterization of SBA, suggest that SBA represents a unique intestinal malignancy and treatments should not be habitually extrapolated from colorectal cancer.Further studies evaluating the benefit of targeted therapies exclusively in SBA and AAC are warranted. Read More

View Article
March 2018
11 Reads